The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 10

PMID 35681689

Authors

Reyes Benot-Dominguez

Annamaria Cimini

Daniela Barone

Antonio Giordano

Francesca Pentimalli

Affiliations

Soon will be listed here.

Abstract

Overweight and obesity constitute the most impactful lifestyle-dependent risk factors for cancer and have been tightly linked to a higher number of tumor-related deaths nowadays. The excessive accumulation of energy can lead to an imbalance in the level of essential cellular biomolecules that may result in inflammation and cell-cycle dysregulation. Nutritional strategies and phytochemicals are gaining interest in the management of obesity-related cancers, with several ongoing and completed clinical studies that support their effectiveness. At the same time, cyclin-dependent kinases (CDKs) are becoming an important target in breast and ovarian cancer treatment, with various FDA-approved CDK4/6 inhibitors that have recently received more attention for their potential role in diet-induced obesity (DIO). Here we provide an overview of the most recent studies involving nutraceuticals and other dietary strategies affecting cell-cycle pathways, which might impact the management of breast and ovarian cancers, as well as the repurposing of already commercialized chemotherapeutic options to treat DIO.

Citing Articles

Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor.

Malon D, Molto C, Prasla S, Cuthbert D, Pathak N, Berner-Wygoda Y Breast Cancer Res Treat. 2024; .

PMID: 39720971 DOI: 10.1007/s10549-024-07578-2.

Diet-induced Obesity: Pathophysiology, Consequences and Target Specific Therapeutic Strategies.

Banerjee M, Pandey V Curr Protein Pept Sci. 2024; 26(2):113-124.

PMID: 39225225 DOI: 10.2174/0113892037329528240827180820.

Multiomics Picture of Obesity in Young Adults.

Kiseleva O, Pyatnitskiy M, Arzumanian V, Kurbatov I, Ilinsky V, Ilgisonis E Biology (Basel). 2024; 13(4).

PMID: 38666884 PMC: 11048234. DOI: 10.3390/biology13040272.

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.

Huang Y, Fan Y, Zhao Z, Zhang X, Tucker K, Staley A Int J Mol Sci. 2023; 24(15).

PMID: 37569750 PMC: 10418904. DOI: 10.3390/ijms241512375.

RNA Sequencing of Intestinal Enterocytes Pre- and Post-Roux-en-Y Gastric Bypass Reveals Alteration in Gene Expression Related to Enterocyte Differentiation, Restitution, and Obesity with Regulation by Schlafen 12.

Vomhof-DeKrey E, Singhal S, Singhal S, Stover A, Rajpathy O, Preszler E Cells. 2022; 11(20).

PMID: 36291149 PMC: 9601224. DOI: 10.3390/cells11203283.

References

Giordano A, Tommonaro G . Curcumin and Cancer. Nutrients. 2019; 11(10). PMC: 6835707. DOI: 10.3390/nu11102376. View

de Groot S, Lugtenberg R, Cohen D, Welters M, Ehsan I, Vreeswijk M . Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020; 11(1):3083. PMC: 7311547. DOI: 10.1038/s41467-020-16138-3. View

Di Zazzo E, Polito R, Bartollino S, Nigro E, Porcile C, Bianco A . Adiponectin as Link Factor between Adipose Tissue and Cancer. Int J Mol Sci. 2019; 20(4). PMC: 6412253. DOI: 10.3390/ijms20040839. View

Zhao J, Chen X, Herjan T, Li X . The role of interleukin-17 in tumor development and progression. J Exp Med. 2019; 217(1). PMC: 7037244. DOI: 10.1084/jem.20190297. View

Huang Bartlett C, Mardekian J, Cotter M, Huang X, Zhang Z, Parrinello C . Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS One. 2020; 15(4):e0227256. PMC: 7173855. DOI: 10.1371/journal.pone.0227256. View

Ryan J, Heckler C, Ling M, Katz A, Williams J, Pentland A . Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res. 2013; 180(1):34-43. PMC: 3998827. DOI: 10.1667/RR3255.1. View

Li J, Zhu F, Lubet R, De Luca A, Grubbs C, Ericson M . Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. Mol Carcinog. 2011; 52(2):134-43. PMC: 3340451. DOI: 10.1002/mc.21839. View

Amjad A, Parikh R, Appleman L, Hahm E, Singh K, Singh S . Broccoli-Derived Sulforaphane and Chemoprevention of Prostate Cancer: From Bench to Bedside. Curr Pharmacol Rep. 2015; 1(6):382-390. PMC: 4635516. DOI: 10.1007/s40495-015-0034-x. View

Juric V, Hudson L, Fay J, Richards C, Jahns H, Verreault M . Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death Dis. 2021; 12(8):763. PMC: 8333061. DOI: 10.1038/s41419-021-04050-7. View

10.

Hu S, Xu Y, Meng L, Huang L, Sun H . Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther Med. 2018; 16(2):1266-1272. PMC: 6090267. DOI: 10.3892/etm.2018.6345. View

11.

Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C . Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2018; 37(3):178-189. DOI: 10.1200/JCO.18.01624. View

12.

McCubrey J, Lertpiriyapong K, Steelman L, Abrams S, Yang L, Murata R . Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY). 2017; 9(6):1477-1536. PMC: 5509453. DOI: 10.18632/aging.101250. View

13.

Menendez J, Vellon L, Lupu R . Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005; 16(8):1253-67. DOI: 10.1093/annonc/mdi239. View

14.

Vaughn D, Hwang W, Lal P, Rosen M, Gallagher M, ODwyer P . Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer. 2014; 121(9):1463-8. DOI: 10.1002/cncr.29213. View

15.

Murphy C, Dickler M . The Role of CDK4/6 Inhibition in Breast Cancer. Oncologist. 2015; 20(5):483-90. PMC: 4425391. DOI: 10.1634/theoncologist.2014-0443. View

16.

Noonan J, Jarzabek M, Lincoln F, Cavanagh B, Pariag A, Juric V . Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers (Basel). 2019; 11(12). PMC: 6966586. DOI: 10.3390/cancers11122005. View

17.

Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F . Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 2008; 53(4):484-7. DOI: 10.1111/j.1365-2559.2008.03121.x. View

18.

Zorn S, Ehret J, Schauble R, Rautenberg B, Ihorst G, Bertz H . Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study. BMC Cancer. 2020; 20(1):578. PMC: 7310229. DOI: 10.1186/s12885-020-07041-7. View

19.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(1):116-124. PMC: 6777264. DOI: 10.1001/jamaoncol.2019.4782. View

20.

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q . FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2018; 24(13):2999-3004. DOI: 10.1158/1078-0432.CCR-17-2369. View